Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
1Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Dr. Hamburg served as Commissioner of the U.S. Food and Drug Administration from May 2009 to April 2015 and has held policy positions across multiple presidential administrations. She currently serves as Co-President of the InterAcademy Partnership and chairs several nonprofit boards focused on public health and biosecurity.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

ALNYLAM PHARMACEUTICALS, INC.

2019-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

ALNYLAM PHARMACEUTICALS, INC.

Open ALNYLAM PHARMACEUTICALS, INC. profile →

Director at ALNYLAM PHARMACEUTICALS, INC.

2019-01-01 → End not stated

current · source reported

Observed: 2026-09-21

ALNYLAM PHARMACEUT…ALNYLAM PHARMACEUTICALS, INC.Marc D. Hamburg

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingALNY DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingBRK-B 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:margaret-a-hamburg
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 12, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Board membership · Source reportedServes on the board of ALNYLAM PHARMACEUTICALS, INC.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 12, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 12, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 12, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 12, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 12, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 12, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

View all sources4 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 12, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1178670/000162828026023923/alny-20260406.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at ALNYLAM PHARMACEUTICALS, INC. (NASDAQ: ALNY)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

    Supports: AI and ML experience · Cybersecurity experience · Technology background

  4. https://www.sec.gov/Archives/edgar/data/1178670/000162828026023923/alny-20260406.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership